Peptide Grading
Research peptide
Cagrilintide
From
$35.00
Vendors
15
Lab tested
-
Key benefits
- Up to 10.8% weight loss in phase 2
- About 12% weight loss at 68 weeks
- Long-acting amylin analog
- Boosts semaglutide in CagriSema
Cagrilintide is based on amylin, a hormone that helps regulate appetite and blood sugar after eating. Its structure was modified from natural amylin to make the peptide last longer. Unlike semaglutide, which mainly targets the GLP-1 receptor, cagrilintide acts through amylin and calcitonin-family receptors. Cagrilintide has also been studied on its own and together with semaglutide.
Peptide Grading lists cagrilintide research materials from different suppliers. Listings can include supplier details, reported specifications, COA, quantities, shipping information, and price per mg.
Typical dose
2.4 mg weekly Once weekly
Once weekly, escalating every 4 weeks
Route
Subcutaneous
Administered via subcutaneous injection once weekly on a consistent day. Injection can be given at any time of day, with or without meals. Rotate injection sites between abdomen, thigh, and upper arm.
Cycle
Continuous Typical duration
Storage
-20°C Refrigerated
Follow vendor guidance
Marketplace
Compare all Cagrilintide vendors
Prices per size, coupon codes, lab reports and shipping.
| Vendor | Price | Coupon | Lab test | Shipping | |
|---|---|---|---|---|---|
 TrustedPeps 5 mg | $35.00 Lowest price$7.00/mg | Not on file | 3 days
| Buy | |
 GenPeptide 5 mg | $40.00 $8.00/mg | Not on file | 2 days
| Buy | |
PRPEPS 5 mg | $40.00 $8.00/mg | Not on file | 2 days
| Buy | |
 PepVida Labs 10 mg | $43.69$170.00 −74.3%$4.37/mg | Not on file | 1-3 days
| Buy | |
Biologix Labs 5 mg | $49.97$59.99 −16.7%$9.99/mg | Not on file | 2 Days
| Buy | |
idunpeptides 10 mg | $49.99 $5.00/mg | Not on file | 3–7 days
| Buy | |
Trulab Peptides 5 mg | $62.00 $12.40/mg | Not on file | 2–5 days
| Buy | |
Giga Compounds 10 mg | $62.10$69.00 −10%$6.21/mg | Not on file | 2 days
| Buy |
United StatesWhat the evidence shows
Cagrilintide has a published phase 2 trial and phase 3 data as one arm of REDEFINE 1, where it was mainly studied as a partner to semaglutide.
On its own it produces moderate weight loss, less than modern GLP-1 drugs, which is why development has focused on the combination.
Safety and regulatory position
Investigational · not approvedCagrilintide is not approved on its own or in any product yet. It is part of CagriSema, which is under FDA review.
In trials, the most common side effects were nausea, constipation and other gastrointestinal effects, plus injection-site reactions.
Research-grade material sold online is not an approved drug. Its identity, purity and amount can't be assumed without independent testing, so check the vendor's batch COA.
FAQ
Frequently asked questions.
No. Cagrilintide is linked mainly to amylin and calcitonin-family receptor activity, rather than direct GLP-1 receptor activity.